Opaleye Management Inc. Pro Qr Therapeutics N.V. Transaction History

Opaleye Management Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$1.99 - $3.66 $1.61 Million - $2.95 Million	-807,000 Reduced 55.27%	653,000 $1.39 Million
Q4 2022 Feb 10, 2023	SELL	$0.8 - $3.7 $1.32 Million - $6.12 Million	-1,655,000 Reduced 53.13%	1,460,000 $5.4 Million
Q3 2022 Nov 14, 2022	BUY	$0.74 - $0.89 $277,500 - $333,750	375,000 Added 13.69%	3,115,000 $2.32 Million
Q2 2022 Aug 15, 2022	BUY	$0.56 - $1.0 $176,400 - $315,000	315,000 Added 12.99%	2,740,000 $2.13 Million
Q1 2022 May 16, 2022	BUY	$0.9 - $8.39 $890,541 - $8.3 Million	989,490 Added 68.93%	2,425,000 $2.2 Million
Q4 2021 Feb 14, 2022	BUY	$6.58 - $8.44 $74,419 - $95,456	11,310 Added 0.79%	1,435,510 $11.5 Million
Q3 2021 Nov 16, 2021	BUY	$5.16 - $8.47 $226,008 - $370,986	43,800 Added 3.17%	1,424,200 $11.9 Million
Q2 2021 Aug 16, 2021	BUY	$5.75 - $7.59 $445,050 - $587,466	77,400 Added 5.94%	1,380,400 $9.3 Million
Q1 2021 May 18, 2021	BUY	$4.14 - $9.22 $5.39 Million - $12 Million	1,303,000 New	1,303,000 $8.61 Million

17.4M

37.7K

21.3K

Ticker PRQR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,362,096
Market Cap $188M
Description
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clin...

Get notified when there are updates to the investment portfolio of Opaleye Management Inc., based on Form 13F filings with the SEC.

Stay updated on Opaleye Management Inc. with notifications on news.